retatrutide study news for weight loss: shows 30% body weight loss Eli Lilly infiltrates anti-obesity market
Description
But union members and leaders are continuing a campaign to restore full coverage for GLP-1 drugs
Retatrutide also remains investigational, with ClinicalTrials.gov listing active or recently updated Phase 3 research records as of May 2026
The question now isnt whether GLP-1s are here to stay
[DOI] [PubMed] [Google Scholar] 53.Alvarez E, Martinez MD, Roncero I, Chowen JA, Garcia-Cuartero B, Gispert JD, Sanz C, Vazquez P, Maldonado A, de Caceres J
It's generally not recommended to replace all meals with meal replacements long-term
